Nautilus is developing a large-scale, single-molecule proteomic analysis technology designed to achieve quantification of >95% of the proteome, in the process delivering extreme sensitivity and scale. Nautilus has set a goal of commercializing its platform by late 2023, with several key internal milestones met across a range of platform design and science activities . . .
